⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
10,655
Total Claims
$5.9M
Drug Cost
1,150
Beneficiaries
$5,112
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+30%
Cost per patient vs peers
$5,112 vs $3,933 avg
+3%
Brand preference vs peers
52.7% vs 51.2% avg
Brand vs Generic
47% generic
Brand: 5,213 claims · $5.6M
Generic: 4,682 claims · $140K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 592 | $1.0M |
| Semaglutide | 531 | $889K |
| Empagliflozin | 307 | $406K |
| Tirzepatide | 189 | $312K |
| Insulin Degludec | 234 | $274K |
| Dapagliflozin Propanediol | 173 | $222K |
| Insulin Glargine,hum.Rec.Anlog | 207 | $210K |
| Insulin Aspart | 117 | $190K |
| Sitagliptin Phosphate | 130 | $155K |
| Insulin Aspart Prot/Insuln Asp | 66 | $142K |
| Insulin Aspart | 126 | $136K |
| Insulin Lispro | 70 | $132K |
| Insulin Detemir | 136 | $130K |
| Insulin Lispro | 98 | $117K |
| Semaglutide | 45 | $108K |
Prescribing Profile
Patient Profile
71
Avg Age
63%
Female
1.89
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About